| Company/Division name | Evonik |
| Parent company | Evonik Industries AG |
| Type of work | Manufacturing |
| Reshoring category: | Foreign Direct Investment |
| Total number of jobs (added or to be added): | 80 |
| Year reshoring announced: | 2022 |
| Year reshoring implemented or to be implemented: | 2025 |
| Domestically, the work will be done: | In-house |
| Capital investment ($): | 220 |
| Country(ies) from which reshored: | Germany |
| City reshored to: | Lafayette |
| State(s) reshored to: | IN |
| If relevant, work nearshored to: | - |
| Industry(ies): | Chemicals |
| Product(s) reshored | mRNA therapies, production of lipid |
| What non-domestic negative factors made offshoring less attractive? | Supply chain interruption risk/Natural disaster risk/Political instability |
| What domestic positive factors made reshoring more attractive? | Eco-system synergies, Government Incentives, Infrastructure, Manufacturing/engineering joint innovation (R&D), Skilled workforce availability/training |
